The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer

Comparative analysis of the clinical efficacy between primary Total Mesorectal Excision (TME) surgery and neoadjuvant chemotherapy combined with TME surgery for low-risk locally advanced rectal cancer. Randomly enrolling eligible patients into either the control group receiving neoadjuvant chemotherapy combined with TME surgery or the experimental group receiving primary TME surgery, and subsequently comparing the clinical outcomes of the two groups

Trial Details

NCT ID
NCT05984485
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Rectal Cancer Colorectal Cancer
Interventions
  • neoadjuvant chemotherapy plus total mesorectal excision
  • total mesorectal excision
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Hengyang, Hunan, China|26.88946,112.61888
  • Shenyang, Liaoning, China|41.79222,123.43278
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Newly diagnosed patients, aged 18 to 75 years;
  • Pathologically confirmed rectal adenocarcinoma;
  • Distance of the lower margin of the rectal tumor lesion from the anal margin \<15cm;
  • High-resolution MRI indicates low-risk locally advanced rectal cancer: T1-3bN1-2 or T3aN0 or T3bN0; no involvement of the anal sphincter; negative …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rectal Cancer Colorectal Cancer Trials on Trialify →